

20 November 2003

Level 14, Cigna House,  
40 Mercer Street, PO Box 10-254  
Wellington 6001, New Zealand  
Phone 64 4 460 4990  
Fax 64 4 460 4995  
www.pharmac.govt.nz

**By facsimile****To: Pharmaceutical Suppliers and other interested parties.****Declining applications for the listing of various acetylcholinesterase inhibitors on the Pharmaceutical Schedule**

We write further to our 14 October 2003 consultation letter on the proposal to decline the applications for listing the following acetylcholinesterase inhibitors in Section B of the Pharmaceutical Schedule, and to decline the pilot project.

<b>Chemical</b>	<b>Brand</b>	<b>Supplier</b>	<b>Strength/Presentation</b>
Donepezil	Aricept	Pfizer	5, and 10 mg tablets
Galantamine	Reminyl	Janssen-Cilag	4, 8 and 12 mg tablets
Rivastigmine	Exelon	Novartis	1.5, 3.0, 4.5 and 6.0 mg capsules

Following requests received during consultation, the proposal will now be considered by PHARMAC's Board at its January 2004 meeting. This will provide additional time for the responses received to-date to be evaluated, and for further submissions to be made.

If you would like to provide any comments on this proposal for consideration by the Board, please forward them to Steffan Crausaz (Therapeutic Group Manager) at PHARMAC by 5pm **Friday, 16 January 2004.**

Yours sincerely



Wayne McNee  
Chief Executive